MedTrace Logo

A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis

NCT02684240 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-08-05

No results posted yet for this study

Summary

This research is being done to determine if Nitazoxanide (NTZ) will cause a significant decrease in the number of M. tuberculosis bacteria in sputum after 14 days of treatment. The study is being conducted at the GHESKIO Centers in Port au Prince Haiti

Conditions

Interventions

DRUG

Nitazoxanide

nitazoxanide 1000 mg orally twice daily with food for 14 days

OTHER

Control

The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Daniel W Fitzgerald, MD · Weill Medical College of Cornell University

  • Carl Nathan, MD · Weill Medical College of Cornell University

  • Jean William Pape, MD · Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-04-11
Completion
2018-04-11

Countries

  • Haiti

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02684240 on ClinicalTrials.gov